BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy Subjects
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 18
- Registration Number
- NCT04163523
- Locations
- 🇦🇺
Cancer Care Wollongong, Wollongong, New South Wales, Australia
🇦🇺Austin Health, Heidelberg, Victoria, Australia
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
- Conditions
- Marginal Zone LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMantle Cell LymphomaWaldenstrom Macroglobulinemia
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 90
- Registration Number
- NCT04116437
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers (Williams) Usor, Aurora, Colorado, United States
🇺🇸Christiana Care, Newark, Delaware, United States
🇺🇸Scri Florida Cancer Specialists South, Fort Myers, Florida, United States
Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 300
- Registration Number
- NCT04068519
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China
🇨🇳Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
🇨🇳The Fifth Affiliated Hospital Sun Yat Sen University, Zhuhai, Guangdong, China
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
- Conditions
- Waldenström Macroglobulinemia
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Registration Number
- NCT04052854
- Locations
- 🇺🇸
Eisenhower Desert Cardiology Center, Rancho Mirage, California, United States
🇺🇸Sansum Clinic and Ridley Tree Cancer Center, Santa Barbara, California, United States
🇺🇸Maryland Oncology Hematology, Pa, Columbia, Maryland, United States
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
- Conditions
- Locally Advanced and Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 449
- Registration Number
- NCT04047862
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Providence Portland Medical Center, Portland, Oregon, United States
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- Drug: Tislelizumab, Carboplatin /Cisplatin, EtoposideDrug: Placebo
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 457
- Registration Number
- NCT04005716
- Locations
- 🇨🇳
The Tumor Hospital Affiliated to Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer
- Conditions
- Locally Advanced or Metastatic Urothelial Bladder Cancer
- Interventions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 113
- Registration Number
- NCT04004221
- Locations
- 🇨🇳
Fudan University Hua Dong Hospital, Shanghai, Shanghai, China
🇨🇳Xiangya Hospital central South University, Changsha, Hunan, China
🇨🇳The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
- Conditions
- Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 510
- Registration Number
- NCT04002297
- Locations
- 🇺🇸
West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 25
- Registration Number
- NCT03994211
- Locations
- 🇬🇪
Arensia Exploratory Medicine Llc, Tbilisi, Georgia
🇵🇱Szpital Luxmed, Warszawa, Poland
🇸🇰Summit Clinical Research, Sro, Bratislava, Slovakia
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 4
- Registration Number
- NCT03991494
- Locations
- 🇬🇧
The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom
🇬🇧Royal Liverpool University Hospital Clinical Research Unit, Liverpool, United Kingdom